Dosimetric comparison of equispaced fields and non-equispaced fields in VMAT and IMRT for Nasal cavity and paranasal sinus cancer
-
摘要:
目的比较调强放射治疗(IMRT)和容积调强治疗(VMAT)不同布野方式在鼻窦鼻腔癌放疗计划中剂量学差异,为临床治疗选择最佳方案提供参考依据。 方法选取10例鼻窦鼻腔癌病例,分别进行IMRT 5野、7野偏分野、均分野和VMAT偏分弧、全弧共面计划设计,综合评估靶区的覆盖率、均匀性HI和适形性CI,危及器官受照剂量和治疗效率。 结果IMRT计划和VMAT计划均能满足临床上对靶区覆盖的要求,但VMAT的靶区覆盖较IMRT略高,且较IMRT的5野差异有统计学意义(P<0.05)。对PTV1的CI,VMAT(包括偏分弧和全弧)较IMRT(包括偏分野和均分野)更好。危及器官受照剂量中,脑干:VMAT较IMRT计划Dmax和D1%都较低,偏分弧D1%较全弧低;晶体、视交叉:VMAT较IMRT有相同或更好的保护效果,Dmax和D1%大部分更低;同侧视神经:VMAT较IMRT的Dmax低;同侧腮腺:VMAT较大部分IMRT的Dmean低;差异有统计学意义(P<0.05)。VMAT的平均机器跳数为IMRT的1/3;VMAT的偏分弧要比全弧跳数略低,差异有统计学意义(P<0.05)。 结论IMRT的偏分野可作为鼻窦鼻腔癌放疗射野设计的考虑方案,在机器条件允许下,VAMT的偏分弧比IMRT偏分野更有优势。 Abstract:ObjectiveTo compare dosimetric differences between intensity modulated radiotherapy( IMRT) and volumetric modulated arc therapy (VMAT) in the radiotherapy plan of nasal cavity and paranasal sinus cancer, provide reference basis for selecting the best clinical treatment. MethodsTen patients with nasal cavity and paranasal sinus cancers were selected. The patients were received the VMAT plans which were created as non-equispaced fields of VMAT and equispaced fields of VMAT, and IMRT plans which were created as non-equispaced fields and equispaced fields of 5 beams and 7 beams. Dosimetry of different design methods were compared to assess the coverage rate, heterogeneity index (HI) and conformity index (CI) in the target volum, exposure dose of the organs at risk and therapeutic efficiency. ResultAll of coverages of IMRT plans and VMAT plans met the criteria of clinic. VMAT plans were still better than IMRT plans, the differences between IMRT plans of 5 beams were significant.For CI of PTV1, VMAT (including partial arc and full arc) were better than IMRT(including non-equispaced fields and equispaced fields) . Exposure dose of the organs at risk: for brain stem, Dmax and D1% of VMAT plans were lower than IMRT plans, and D1% of partial arc were lower than full arc (P<0.05). For Lens, VMAT plans had a same or better protective effect than IMRT plans, Dmax and D1% of VMAT plans were lower than most of those of IMRT(P<0.05). For Optic nerves-Ipsilateral, Dmax of VMAT plans were lower than those of IMRT (P<0.05). For Chiasm, Dmax and D1% of VMAT plans were lower than most of those of IMRT (P<0.05). For Parotid-Ipsilateral, Dmean of VMAT plans were lower than most of those of IMRT(P<0.05). Compared with IMRT plans, VMAT plans showed fewer MUs (about 1/3) (P<0.05). ConclusionNon-equispaced field can be considered as the radiotherapy field design of Nasal cavity and paranasal sinus cancer.Depending on the machine conditions, the partial arc of VMAT is more advantageous than the non-equispaced fields of IMRT. -
表 1 靶区PTVs和危及器官优化条件
器官 剂量-体积 目标 PGTV V100% ≥99% Dmax ≤72.6 Gy PTV1 V100% ≥99% V110% ≤10% Dmax ≤66 Gy Brain Stem Dmax ≤54 Gy Brain Stem+3 mm Dmax ≤60 Gy Lens Dmax ≤0.8 Gy Eyes Dmax ≤50 Gy Dmean ≤35 Gy Optic nerves, Chiasm Dmax ≤54 Gy Parotid glands V30 ≤50% Dmean ≤40 Gy V100%:超过规定剂量100%的体积百分比;Dmax:最大剂量;V110%:超过规定剂量110%的体积百分比;Dmean:平均剂量;V30:>30 Gy的体积百分比. 表 2 靶区的均匀性HI和适形性CI比较
Item Field 5F-N 5F-E 7F-N 7F-E Arc-N Arc-E PGTV的CI比较 PGTV.CI(SD) 0.719(0.127) 0.733(0.130) 0.738(0.136) 0.750(0.151) 0.721(0.165) 0.725(0.178) P(Arc-N vs.) 0.974 0.852 0.795 0.665 — 0.947 P(Arc-E vs.) 0.921 0.904 0.847 0.714 0.947 — PGTV的HI比较 PGTV.HI(SD) 0.088(0.014) 0.093(0.016) 0.092(0.015) 0.088(0.014) 0.088(0.014) 0.092(0.022) P(Arc-N vs.) 0.965 0.45 0.602 0.965 — 0.551 P(Arc-E vs.) 0.58 0.874 0.94 0.58 0.551 — PTV1的CI比较 PTV1.CI(SD) 0.828(0.038) 0.834(0.026) 0.865(0.024) 0.860(0.031) 0.885(0.019) 0.888(0.020) P(Arc-N vs.) 0.000 0.000 0.049 0.041 — 0.799 P(Arc-E vs.) 0.000 0.000 0.038 0.023 0.799 — 表 3 IMRT计划和VMAT计划中危及器官的剂量分布比较结果
指标 Field 5F-N 5F-E 7F-N 7F-E Arc-N Arc-E 脑干Dmax Dmax(SD) 4366(166) 4278(165) 4117(233) 3987(145) 3826(195) 3961(210) P(Arc-N vs.) 0.000 0.000 0.001 0.061 — 0.115 P(Arc-E vs.) 0.000 0.000 0.068 0.756 0.115 — 脑干D1% D1%(SD) 3856(165) 3802(135) 3564(180) 3532(132) 3416(157) 3532(165) P(Arc-N vs.) 0.000 0.000 0.039 0.104 — 0.008 P(Arc-E vs.) 0.000 0.000 0.644 0.998 0.008 — Len-Ipsilateral Dmax Dmax(SD) 1123(51) 1094(50) 1088(40) 1103(40) 1066(53) 1099(53) P(Arc-N vs.) 0.011 0.2 0.317 0.095 — 0.137 P(Arc-E vs.) 0.265 0.833 0.62 0.851 0.137 — Len-Ipsilateral D1% D1%(SD) 1066(44) 1036(42) 1038(36) 1052(36) 998(47) 1032(51) P(Arc-N vs.) 0.001 0.054 0.044 0.007 — 0.084 P(Arc-E vs.) 0.086 0.833 0.765 0.298 0.084 — Len-Contralateral Dmax Dmax(SD) 1000(51) 957(42) 997(40) 990(39) 917(54) 926(44) P(Arc-N vs.) 0.000 0.056 0.000 0.001 — 0.661 P(Arc-E vs.) 0.001 0.135 0.001 0.003 0.661 — Len-Contralateral D1% D1%(SD) 949(44) 920(40) 953(38) 949(37) 873(50) 881(42) P(Arc-N vs.) 0.000 0.015 0.000 0.000 — 0.665 P(Arc-E vs.) 0.001 0.042 0.000 0.001 0.665 — Eye-Ipsilateral Dmax Dmax(SD) 4982(230) 4984(252) 4849(223) 4809(219) 4853(209) 4869(219) P(Arc-N vs.) 0.206 0.2 0.971 0.664 — 0.875 P(Arc-E vs.) 0.266 0.259 0.847 0.555 0.875 — Eye-Ipsilateral D1% D1%(SD) 4299(231) 4291(248) 4269(227) 4209(215) 4180(188) 4174(189) P(Arc-N vs.) 0.228 0.262 0.366 0.768 — 0.945 P(Arc-E vs.) 0.203 0.234 0.331 0.716 0.945 — Eye-Contralateral Dmax Dmax(SD) 3807(158) 3779(138) 3807(150) 3697(120) 3816(109) 3747(116) P(Arc-N vs.) 0.888 0.536 0.889 0.051 — 0.252 P(Arc-E vs.) 0.314 0.595 0.313 0.405 0.252 — Eye-Contralateral D1% D1%(SD) 3354(171) 3277(147) 3339(168) 3236(137) 3307(130) 3217(133) P(Arc-N vs.) 0.477 0.661 0.625 0.291 — 0.182 P(Arc-E vs.) 0.043 0.366 0.071 0.776 0.182 — Optic nerve-Ipsilateral Dmax Dmax(SD) 5739(60) 5781(66) 5528(62) 5571(69) 5440(63) 5449(60) P(Arc-N vs.) 0.000 0.000 0.003 0.000 — 0.73 P(Arc-E vs.) 0.000 0.000 0.008 0.000 0.73 — Optic nerve-Ipsilateral D1% D1%(SD) 5524(78) 5554(77) 5277(81) 5364(81) 5294(64) 5296(56) P(Arc-N vs.) 0.000 0.000 0.624 0.038 — 0.94 P(Arc-E vs.) 0.000 0.000 0.572 0.045 0.94 — Optic nerve-Contralateral Dmax Dmax(SD) 5361(82) 5447(80) 5348(74) 5309(76) 5374(107) 5243(95) P(Arc-N vs.) 0.75 0.064 0.508 0.099 — 0.001 P(Arc-E vs.) 0.004 0.000 0.009 0.097 0.001 — Optic nerve-Contralateral D1% D1%(SD) 5184(94) 5306(88) 5155(91) 5147(91) 5139(98) 5102(104) P(Arc-N vs.) 0.294 0.000 0.704 0.85 — 0.38 P(Arc-E vs.) 0.057 0.000 0.211 0.287 0.38 — 视交叉Dmax Dmax(SD) 5751(116) 5797(103) 5700(132) 5850(82) 5614(118) 5635(127) P(Arc-N vs.) 0.009 0.001 0.097 0.000 — 0.679 P(Arc-E vs.) 0.027 0.002 0.208 0.000 0.679 — 视交叉D1% D1%(SD) 5599(141) 5638(120) 5516(156) 5811(123) 5478(139) 5494(140) P(Arc-N vs.) 0.053 0.012 0.537 0.000 — 0.791 P(Arc-E vs.) 0.093 0.022 0.724 0.000 0.791 — 同侧腮腺Dmean Dmean(SD) 1346(16) 1242(17) 1442(45) 1432(44) 1304(20) 1358(40) P(Arc-N vs.) 0.24 0.107 0.006 0.008 — 0.147 P(Arc-E vs.) 0.729 0.012 0.043 0.067 0.147 — 对侧腮腺Dmean Dmean(SD) 1289(97) 1069(24) 1246(78) 1137(47) 1058(34) 992(33) P(Arc-N vs.) 0.007 0.854 0.018 0.227 — 0.304 P(Arc-E vs.) 0.002 0.236 0.005 0.048 0.304 — Dmax:最大剂量;D1%:DVH的1%体积对应的剂量;Dmean:平均剂量. 表 4 机器跳数比较
Field 5F-N 5F-E 7F-N 7F-E Arc-N Arc-E MUsmean(SD) 934.8(62.8) 844.5(43.5) 940.6(46.4) 903.6(43.0) 377.1(9.7) 393.4(11.0) p value(Arc-N vs.) 0.000* 0.000* 0.000* 0.000* – 0.003* p value(Arc-E vs.) 0.000* 0.000* 0.000* 0.000* 0.003* – -
[1] Roush GC. Epidemiology of cancer of the nose and paranasal sinuses: current concepts[J]. Head Neck Surg, 2010, 2(1): 3-11. [2] Muir CS, Nectoux J. Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses[J]. Clin Otolaryngol Allied Sci, 1980, 5(3): 195-211. doi: 10.1111/coa.1980.5.issue-3 [3] Jeong Y, Lee SW, Kwak J, et al. A dosimetric comparison of volumetric modulated arc therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer[J]. Radiat Oncol, 2014, 9(1): 193-205. doi: 10.1186/1748-717X-9-193 [4] Qi F, Wang WH, He XH, et al. Phase 2 study of first-line intensity modulated radiation therapy followed by gemcitabine, dexamethasone, and cisplatin for High-Risk, early stage extranodal Nasal-Type NK/T-Cell lymphoma: the GREEN study[J]. Int J Radiat Oncol Biol Phys, 2018, 102(1): 61-70. doi: 10.1016/j.ijrobp.2018.05.046 [5] Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2004, 60(5): 1440-50. doi: 10.1016/j.ijrobp.2004.05.022 [6] Xu LM, Kang ML, Jiang B, et al. A study of the dosimetric characteristics between different fixed-field IMRT and VMAT in early-stage primary mediastinal B-cell lymphoma[J]. Med Dosim, 2018, 43(1): 91-9. doi: 10.1016/j.meddos.2017.08.010 [7] Bortfeld T, Webb S. Single-Arc IMRT[J]. Phys Med Biol, 2009, 54(1): N9-20. doi: 10.1088/0031-9155/54/1/N02 [8] 覃 文, 黎桂华, 张大伟, 等. 鼻腔NK/T细胞淋巴瘤RapidArc容积旋转调强与动态适形调强的剂量学比较[J]. 中国癌症防治杂志, 2015, 7(3): 201-5. doi: 10.3969/j.issn.1674-5671.2015.03.13 [9] 胡 江. 早期结外鼻腔NK/T细胞淋巴瘤固定野调强和旋转调强放疗的剂量学比较[J]. 中华放射医学与防护杂志, 2014, 34(2): 116-9. doi: 10.3760/cma.j.issn.0254-5098.2014.02.010 [10] Zieminski S, Khandekar M, Wang Y. Assessment of multi-criteria optimization (MCO) for volumetric modulated arc therapy (VMAT) in hippocampal avoidance whole brain radiation therapy (HA-WBRT)[J]. J Appl Clin Med Phys, 2018, 19(2): 184-90. doi: 10.1002/acm2.2018.19.issue-2 [11] 郭 蕊, 孙 颖, 黄劭敏, 等. 鼻咽癌容积旋转调强放疗与常规静态调强放疗的剂量学对比研究[J]. 中山大学学报: 医学科学版, 2012, 33(6): 835-40, 855. [12] Schakel T, Peltenburg B, Dankbaar JW, et al. Evaluation of diffusion weighted imaging for tumor delineation in head-and-neck radiotherapy by comparison with automatically segmented,18 F-fluorodeoxyglucose positron emission tomography[J]. Physic Imag Radiat Oncol, 2018, 5: 13-8. doi: 10.1016/j.phro.2017.12.004 [13] Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)[J]. Strahlenther Onkol, 2012, 188(1): 97-9. doi: 10.1007/s00066-011-0015-x [14] Feuvret L, Noël G, Mazeron JJ, et al. Conformity index: a review[J]. Int J Radiat Oncol Biol Phys, 2006, 64(2): 333-42. doi: 10.1016/j.ijrobp.2005.09.028 [15] Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma:Are we making progress:a series of 220 patients and a systematic review[J]. Cancer, 2001, 92(12): 3012-29. doi: 10.1002/(ISSN)1097-0142 [16] 周洪波, 彭美霞, 曾志强, 等. 肺癌放疗中不同布野方式对剂量分布影响的探讨[J]. 江西医药, 2017, 23(8): 774-5. doi: 10.3969/j.issn.1006-2238.2017.08.020 [17] Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc[J]. Med Phys, 2008, 35(1): 310-7. [18] Li Y, Wang J, Tan L, et al. Dosimetric comparison between IMRT and VMAT in irradiation for peripheral and central lung cancer[J]. Oncol Lett, 2018, 15(3): 3735-45. [19] 李润霄, 韩 春, 焦广青, 等. 上颌窦癌调强放疗布野方向对剂量分布的影响[C]//第五届中国肿瘤学术大会暨第七届海峡两岸肿瘤学术会议, 2008. [20] 蔡俊涛, 陈 凡, 王 财, 等. 非小细胞肺癌容积旋转调强与适形调强放疗的剂量学比较[J]. 中国医学物理学杂志, 2018, 35(4): 23-7. [21] 熊 超, 叶 威, 王 璐, 等. VMAT和IMRT技术在鼻咽癌放疗海马保护中可行性研究[J]. 中国现代医生, 2018, 56(8): 79-81. [22] 刘建平, 杨海芳, 王志武, 等. 部分弧容积旋转调强计划在中央型肺癌的应用[J]. 中国医学物理学杂志, 2017, 34(11): 1091-5. doi: 10.3969/j.issn.1005-202X.2017.11.003